[{"id":"245ed9e1-ca34-4788-8cc3-6546ba073450","acronym":"","url":"https://clinicaltrials.gov/study/NCT06573398","created_at":"2025-02-27T08:15:39.768Z","updated_at":"2025-02-27T08:15:39.768Z","phase":"Phase 2","brief_title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","source_id_and_acronym":"NCT06573398","lead_sponsor":"Ruijin Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":"","alterations":" ","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-08-27"},{"id":"495ae210-14e3-4dc2-9bda-5e696bcb61a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056804","created_at":"2023-11-19T01:16:40.961Z","updated_at":"2024-07-02T16:35:28.894Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","source_id_and_acronym":"NCT06056804","lead_sponsor":"Beijing Friendship Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":" | ","alterations":" CD163 expression • CD4 expression","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD163 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • capecitabine • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-11-17"},{"id":"5aa9101f-5e17-4f18-aed0-af281c1f2b88","acronym":"R-2","url":"https://clinicaltrials.gov/study/NCT05898451","created_at":"2023-06-12T16:09:02.706Z","updated_at":"2024-07-02T16:35:45.921Z","phase":"Phase 2","brief_title":"Effect of Refnot on Immunity in Cancer Patients","source_id_and_acronym":"NCT05898451 - R-2","lead_sponsor":"Refnot-Pharm Ltd","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • dacarbazine • lomustine • Zadaxin (thymalfasin)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 06/04/2009","start_date":" 06/04/2009","primary_txt":" Primary completion: 11/01/2011","primary_completion_date":" 11/01/2011","study_txt":" Completion: 11/01/2011","study_completion_date":" 11/01/2011","last_update_posted":"2023-06-12"},{"id":"ea0c53d9-0e27-4fe3-9b50-8dd33dab412e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02787447","created_at":"2021-01-18T13:40:29.924Z","updated_at":"2024-07-02T16:37:27.452Z","phase":"Phase 2","brief_title":"Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy","source_id_and_acronym":"NCT02787447","lead_sponsor":"First People's Hospital of Hangzhou","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • Conmana (icotinib) • Zadaxin (thymalfasin)"],"overall_status":"Unknown status","enrollment":" Enrollment 46","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2016-11-25"},{"id":"38c137c0-c4b9-44f1-9e5a-7a959f504448","acronym":"","url":"https://clinicaltrials.gov/study/NCT02906150","created_at":"2021-01-18T14:15:39.027Z","updated_at":"2024-07-02T16:37:29.012Z","phase":"Phase 2","brief_title":"Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type","source_id_and_acronym":"NCT02906150","lead_sponsor":"SciClone Pharmaceuticals","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Zadaxin (thymalfasin)"],"overall_status":"Unknown status","enrollment":" Enrollment 140","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2016-09-19"}]